China Biologic Reports Financial Results for the Second Quarter of 2019
--2Q19 Total Sales Up 12.7% YoY in USD terms, or 20.4% YoY in RMB terms; Net Income Up 45.5% YoY to$41.6 Million; Non-GAAP Adjusted Net Income Up 29.1% YoY in RMB terms-- --1H19 Total Sales Up 14.0% YoY in USD terms, or 21.3% YoY in RMB terms; Net Income Up 31.7% YoY to$79.3 Million; Non-GAA...
China Biologic Products to Report Second Quarter 2019 Financial Results
BEIJING, July 26, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its second quarter 2019 financial resu...
China Biologic Reports Financial Results for the First Quarter of 2019
--1Q19 Total Sales Up 15.4% YoY in USD terms, or 22.3% YoY in RMB terms; Net Income Up 19.3% YoY to $37.7 Million; Non-GAAP Adjusted Net Income Up 14.3% YoY in RMB terms -- BEIJING, May 10, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"...
China Biologic Products to Report First Quarter 2019 Financial Results
BEIJING, April 30, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company plans to release its first quarter 2019 financial results ...
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2018
-- 4Q18 Total Sales Up 27.5% YoY in USD terms, or 33.5% YoY in RMB terms; Net Income Up $59.4 Million YoY to $34.8 Million; Non-GAAP Adjusted Net Income Up 23.9% YoY in RMB terms -- -- FY18 Total Sales Up 26.1% YoY in USD terms, or 23.5% YoY in RMB terms; Net Income Up 88.7% YoY to $128.1 Million; ...
China Biologic Products to Report Fourth Quarter and Fiscal Year 2018 Financial Results
BEIJING, Feb. 25, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company plans to release its fourth quarter and fiscal year 2018 fi...
China Biologic Reiterates Full Year 2018 Financial Forecast
BEIJING, Jan. 7, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO)("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today reiterated its previously revised full year 2018 forecast. Full year 2018 non-GAAP adju...
China Biologic Announces Dismissal of Lawsuit Filed in Cayman Islands by Former Chairman
BEIJING, Dec. 14, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Grand Court of theCayman Islands (the "Court") dismissed the lawsui...
China Biologic Reports Financial Results for the Third Quarter of 2018
3Q18 Total Sales Up 21.9% YoY in RMB terms, or 19.6% YoY in USD terms; Non-GAAP Adjusted Net Income Down 12.7% YoY in RMB terms; Net Income Up 4.1% YoY to $32.9 Million Board of Directors Approves $100 Million Share Repurchase Program BEIJING, Nov. 1, 2018 /PRNewswire/ -- China Biologic Products...
China Biologic Products to Report Third Quarter 2018 Financial Results
BEIJING, Oct. 24, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company plans to release its third quarter 2018 financial results o...
China Biologic Responds to Lawsuit Filed in Cayman Islands by Former Chairman
BEIJING, Aug. 28, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today issued the following statement in response to a lawsuit filed against the Company in t...
China Biologic Announces Updates on Unsolicited Acquisition Proposals and Strategic Private Placement
BEIJING, Aug. 24, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company's board of directors (the "Board") has received a letter da...
China Biologic Announces Receipt of Competing Non-Binding Acquisition Proposal
BEIJING, Aug. 21, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that its board of directors (the "Board") has received an unsolicited, preli...
China Biologic Names Bing Li as New CEO
BEIJING, Aug. 13, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company's Board of Directors (the "Board") has appointed Dr. Bing L...
China Biologic Reports Financial Results for the Second Quarter of 2018
-- 2Q18 Total Sales Up 25.5% YoY and Non-GAAP Adjusted Net Income Down 2.8% YoY in RMB terms, or Total Sales Up 34.8% YoY to $120.4 Million and Net Income Down 7.7% YoY to $28.6 Million in USD terms -- -- 1H18 Total Sales Up 19.5% YoY and Non-GAAP Adjusted Net Income Down 0.4% YoY in RMB terms,...
China Biologic Products to Report Second Quarter 2018 Financial Results
BEIJING, July 27, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company plans to release its second quarter 2018 financial results ...
China Biologic Announces Results of Its 2018 Annual General Meeting of Shareholders
BEIJING, July 2, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("CBPO" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced the results of the Company's 2018 Annual General Meeting of Shareholders (the "Annual ...
China Biologic Announces Receipt of Non-Binding Acquisition Proposal
BEIJING, June 19, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("CBPO" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that its board of directors (the "Board") has received an unsolicited, preliminary non...
China Biologic Receives CFDA Clinical Trial Approval for Human Fibrin Sealant
BEIJING, June 11, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that Shandong Taibang Biological Products Co. Ltd., the Company's majority...
China Biologic Reports Financial Results for the First Quarter of 2018
--1Q18 Total Sales Up 13.7% YoY and Non-GAAP Adjusted Net Income Up 2.1% YoY in RMB terms, or Total Sales Up 23.0% YoY to $112.5 Million and Net Income Up 5.3% YoY to $31.6 Million in USD terms-- BEIJING, May 4, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China ...
